REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial

Hypertension Clinical Trial

— REVERENT  

Official title:

Short - Medium and Long Term Blood Pressure Variability in Essential Hypertensive Patients Treated With Nifedipine GITS or Ramipril - a Randomized Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02499822
• Other study ID #: 09F401
• Status: Completed
• Phase: Phase 4
• Start date: October 2015
• Est. completion date: November 1, 2020

Study information

• Verified date: September 2021
• Source: Istituto Auxologico Italiano
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is 1. to compare the effects of nifedipine GITS and ramipril on blood pressure variability in subjects with elevated blood pressure variability. 2. to assess whether the degree of treatment-induced changes in blood pressure variability, is related to the degree of regression (or progression) of organ damage in heart, kidneys and carotid arteries.

Description:

Elevated blood pressure variability (BPV) is associated with adverse cardiovascular outcomes and organ damage in hypertensive subjects. An antihypertensive treatment able to reduce BPV independently of BP lowering effect might thus provide additional protection in terms of cardiovascular risk in subjects with elevated BPV, independently on its effect of BP itself. However, data on the effects of different classes of antihypertensive drugs on BPV are limited and inconsistent. Some studies have suggested a possible usefulness of calcium antagonists in this setting. Based on the above considerations the investigators hypothesize that a calcium channel blocker nifedipine GITS, will provide a greater BPV lowering effect, when compared with ramipril, independently from the reduction in mean BP level. Based on the above considerations, the primary objective of this study is to compare the effects of nifedipine GITS and ramipril on different estimates of BPV (24 h BPV, home BPV, and visit-to-visit BPV) in subjects with elevated BPV. The secondary objective is to assess whether the degree of treatment-induced changes in BPV, is related to the degree of regression (or progression) of organ damage, after accounting for mean BP reduction by treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 168
• Est. completion date: November 1, 2020
• Est. primary completion date: July 3, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male and female subjects
• Age 35-75 years
• Clinic systolic BP =140 mmHg and/or diastolic BP = 90 mmHg (under no antihypertensive treatment)
• Daytime BP on ambulatory BP monitoring (ABPM) =135 mmHg systolic and/or =85 mmHg diastolic (under no antihypertensive treatment)
• Home SBP standard deviation (SD) >7 mmHg and/or daytime ambulatory SBP SD >12 mmHg
• Patients may be included if untreated or, if treated with one antihypertensive drug or two drugs in low doses, after 2 weeks' washout period
• Written informed consent to participate in the study

Exclusion Criteria:

• Subjects treated with = 2 antihypertensive drugs (except those on two drugs in low doses)
• Treated subjects with on-treatment clinic BP =160 mmHg systolic and/or 100 mmHg diastolic
• Treated antihypertensive subjects in whom withdrawal of treatment is deemed unethical by the investigator (e.g. because of the existence of compelling indications other than hypertension for continuous use of previously used antihypertensive agent)
• Contraindications to study treatments as detailed in the relative Summaries of Medical Product Characteristics for ramipril (hypersensitivity to ramipril or any of the excipients or any other ACE inhibitor, history of angioneurotic oedema, extracorporeal treatments leading to contact of blood with negatively charged surfaces, significant bilateral renal artery stenosis or renal artery stenosis in a single functioning kidney, second and third trimesters of pregnancy, lactation, haemodynamically relevant renal artery stenosis, hypotensive or haemodynamically unstable patients) or nifedipine GITS (known hypersensitivity to nifedipine or to any of the excipients, pregnancy before week 20 and during breastfeeding, cardiovascular shock, concomitant treatment with rifampicin, patients with a Kock pouch)
• Cardiovascular diseases other than hypertension (coronary heart disease, heart failure or left ventricular systolic dysfunction of any degree, atrial fibrillation or frequent arrhythmias, valvular or congenital heart disease, cardiomyopathies, cerebrovascular disease, peripheral artery disease, aortic aneurysm)
• Chronic kidney disease
• Suspected or confirmed secondary hypertension
• Diabetes mellitus
• Subjects with conditions other than those mentioned above, where compelling indications for the use of any specific class of antihypertensive medication exist, according to current (e.g. European Society of Cardiology) guidelines
• Other conditions deemed relevant by the investigator (including respiratory disorders, liver disease, renal disease, thyroid disorders)
• BMI =35 kg/m2
• Known severe obstructive sleep apnea (apnea-hypopnea index > 30 or use of CPAP)
• Premenopausal women not using effective contraceptive methods
• Elevated probability of noncompliance with the study procedures

Related Conditions & MeSH terms

• High Blood Pressure Variability
• Hypertension

Intervention

Drug:
• Nifedipine GITS
Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
• Ramipril
Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.

Locations

Country	Name	City	State
China	Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital Shanghai Institute of Hypertension, Shanghai Jiaotong University School of Medicine	Shanghai
Greece	Hypertension Center, Third University Department of Medicine, Sotiria Hospital	Athens
Italy	Istituto Auxologico Italiano	Milan

Sponsors (2)

Lead Sponsor	Collaborator
Istituto Auxologico Italiano	Bayer

Countries where clinical trial is conducted

China,  Greece,  Italy, 

References & Publications (10)

Levi-Marpillat N, Macquin-Mavier I, Tropeano AI, Parati G, Maison P. Antihypertensive drug classes have different effects on short-term blood pressure variability in essential hypertension. Hypertens Res. 2014 Jun;37(6):585-90. doi: 10.1038/hr.2014.33. Epub 2014 Mar 27. — View Citation

Liu JG, Xu LP, Chu ZX, Miao CY, Su DF. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens. 2003 Oct;21(10):1961-7. — View Citation

Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens. 2012 Jun;30(6):1241-51. doi: 10.1097/HJH.0b013e32835339ac. — View Citation

Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc. — View Citation

Matsui Y, O'Rourke MF, Hoshide S, Ishikawa J, Shimada K, Kario K. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study. Hypertension. 2012 Jun;59(6):1132-8. doi: 10.1161/HYPERTENSIONAHA.111.189217. Epub 2012 Apr 30. — View Citation

Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol. 2013 Mar;10(3):143-55. doi: 10.1038/nrcardio.2013.1. Epub 2013 Feb 12. Review. Erratum in: Nat Rev Cardiol. 2014 Jun;11(6):314. — View Citation

Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010 Mar 13;375(9718):895-905. doi: 10.1016/S0140-6736(10)60308-X. — View Citation

Ushigome E, Fukui M, Hamaguchi M, Tanaka T, Atsuta H, Ohnishi M, Oda Y, Yamazaki M, Hasegawa G, Nakamura N. Beneficial effect of calcium channel blockers on home blood pressure variability in the morning in patients with type 2 diabetes. J Diabetes Investig. 2013 Jul 8;4(4):399-404. doi: 10.1111/jdi.12052. Epub 2013 Mar 4. — View Citation

Wang JG, Yan P, Jeffers BW. Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials. J Am Soc Hypertens. 2014 May;8(5):340-9. doi: 10.1016/j.jash.2014.02.004. Epub 2014 Feb 15. Review. — View Citation

Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010 Mar 13;375(9718):906-15. doi: 10.1016/S0140-6736(10)60235-8. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Variability (standard deviation) of home systolic blood pressure at final visit		After 10 weeks of study treatment
Secondary	Variability (standard deviation) of home diastolic blood pressure measured at final visit		At baseline and after 10 weeks of study treatment
Secondary	Short term 24h variability of systolic blood pressure at final visit (24h weighted standard deviation)		At baseline and after 10 weeks of study treatment
Secondary	Short term 24h variability of diastolic blood pressure at final visit (24h weighted standard deviation)		At baseline and after 10 weeks of study treatment
Secondary	Visit-to-visit variability (standard deviation) of systolic blood pressure assessed over the three last visits		At baseline and after 6, 8 and 10 weeks of study treatment
Secondary	Visit-to-visit variability (standard deviation) of diastolic blood pressure assessed over the three last visits		At baseline and after 6, 8 and 10 weeks of study treatment
Secondary	Mean 24 hour systolic blood pressure at final visit		At baseline and after 10 weeks of study treatment
Secondary	Mean 24 hour diastolic blood pressure at final visit		At baseline and after 10 weeks of study treatment
Secondary	Sokolow index at the end of the extension study		At baseline and after 12 months of study treatment
Secondary	Cornell voltage duration index at the end of the extension study		At baseline and after 12 months of study treatment
Secondary	Left ventricular mass index at the end of the extension study		At baseline and after 12 months of study treatment
Secondary	Microalbuminuria (albumin-creatinine ratio) at the end of the extension study		At baseline and after 12 months of study treatment
Secondary	Estimated glomerular filtration rate (eGFR, by CKD-EPI formula) at the end of the extension study		At baseline and after 12 months of study treatment
Secondary	Carotid-femoral pulse wave velocity (cfPWV) at the end of the extension study		At baseline and after 12 months of study treatment